吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GILD 吉利德科学

交易中 04-18 12:14:46 EDT

65.99

-0.94

-1.40%

最高67.02	最低65.90	成交量238.98万
今开67.01	昨收66.93	日振幅1.67%
总市值822.88亿	流通市值821.14亿	总股本12.47亿
成交额1.59亿	换手率0.19%	流通股本12.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"GILD","market":"US","secType":"STK","nameCN":"吉利德科学","latestPrice":65.99,"timestamp":1713456881520,"preClose":66.93,"halted":0,"volume":2389790,"delay":0,"floatShares":1244337698,"shares":1246969303,"eps":4.5,"marketStatus":"交易中","marketStatusCode":2,"change":-0.94,"latestTime":"04-18 12:14:46 EDT","open":67.01,"high":67.015,"low":65.9,"amount":158599417.0618,"amplitude":0.016659,"askPrice":65.99,"askSize":160,"bidPrice":65.98,"bidSize":515,"shortable":3,"etf":0,"ttmEps":4.5,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1713470400000},"adr":0,"listingDate":696056400000,"adjPreClose":66.93,"adrRate":0,"dividendRate":0.045461,"preHourTrading":{"tag":"盘前","latestPrice":67.02,"preClose":66.93,"latestTime":"09:29 EDT","volume":10044,"amount":673010.6745600001,"timestamp":1713446999999},"postHourTrading":{"tag":"盘后","latestPrice":67.099,"preClose":66.93,"latestTime":"19:53 EDT","volume":437195,"amount":29261977.7555,"timestamp":1713398012560},"volumeRatio":0.949539},"requestUrl":"/m/hq/s/GILD","defaultTab":"news","newsList":[{"id":"2428567780","title":"瑞银：维持Gilead Sciences(GILD.US)评级，由中性调整至中性评级, 目标价由81.00美元调整至75.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428567780","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428567780?lang=zh_cn&edition=full","pubTime":"2024-04-18 19:36","pubTimestamp":1713440183,"startTime":"0","endTime":"0","summary":"瑞银：维持Gilead Sciences(GILD.US)评级，由中性调整至中性评级, 目标价由81.00美元调整至75.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181936268b35e18e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181936268b35e18e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426783006","title":"BUZZ-Nurix Therapeutics 在增发 1.75 亿美元股票后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2426783006","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426783006?lang=zh_cn&edition=full","pubTime":"2024-04-12 19:37","pubTimestamp":1712921821,"startTime":"0","endTime":"0","summary":"    4月12日 - ** Nurix Therapeutics Inc 的    股价在隔夜后续定价后盘前下跌 5.3%，报 16.30 美元。** 生物制药公司周四晚些时候宣布，  ~1170万股，包括150万份预筹资认股权证，发行价为15美元，筹资总额为1.75亿美元。** Nurix本月早些时候宣布延长与吉利德科学公司  的合作。2023 年第四季度，该公司与辉瑞  达成新的合作。** Nurix 拥有约 4 920 万股已发行股票，市值约 8.46 亿美元** 截至本周四，公司股价已累计上涨 67** 摩根大通、Piper Sandler 和 Stifel 担任股票发行的账簿管理人","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426296458","title":"吉利德科学上涨1.25%，报68.97美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426296458","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426296458?lang=zh_cn&edition=full","pubTime":"2024-04-12 02:08","pubTimestamp":1712858894,"startTime":"0","endTime":"0","summary":"4月12日，吉利德科学(GILD)盘中上涨1.25%，截至02:08，报68.97美元/股，成交2.17亿美元。财务数据显示，截至2023年12月31日，吉利德科学收入总额271.16亿美元，同比减少0.6%；归母净利润56.65亿美元，同比增长23.37%。大事提醒：4月25日，吉利德科学将于(美东)盘后披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/12020840206400.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2425341542","title":"吉利德科学下跌1.23%，报70.02美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2425341542","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425341542?lang=zh_cn&edition=full","pubTime":"2024-04-05 02:35","pubTimestamp":1712255745,"startTime":"0","endTime":"0","summary":"4月5日，吉利德科学(GILD)盘中下跌1.23%，截至02:35，报70.02美元/股，成交2.25亿美元。财务数据显示，截至2023年12月31日，吉利德科学收入总额271.16亿美元，同比减少0.6%；归母净利润56.65亿美元，同比增长23.37%。大事提醒：4月25日，吉利德科学将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/05023540127771.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2424846875","title":"吉利德科学下跌1.22%，报71.21美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2424846875","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2424846875?lang=zh_cn&edition=full","pubTime":"2024-04-04 02:30","pubTimestamp":1712169021,"startTime":"0","endTime":"0","summary":"4月4日，吉利德科学(GILD)盘中下跌1.22%，截至02:30，报71.21美元/股，成交1.73亿美元。财务数据显示，截至2023年12月31日，吉利德科学收入总额271.16亿美元，同比减少0.6%；归母净利润56.65亿美元，同比增长23.37%。大事提醒：4月25日，吉利德科学将披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/04023040122363.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2424209790","title":"吉利德科学下跌1.21%，报72.0美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2424209790","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2424209790?lang=zh_cn&edition=full","pubTime":"2024-04-03 01:35","pubTimestamp":1712079326,"startTime":"0","endTime":"0","summary":"4月3日，吉利德科学(GILD)盘中下跌1.21%，截至01:35，报72.0美元/股，成交1.8亿美元。财务数据显示，截至2023年12月31日，吉利德科学收入总额271.16亿美元，同比减少0.6%；归母净利润56.65亿美元，同比增长23.37%。大事提醒：4月25日，吉利德科学将披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/03013540103960.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2423171813","title":"吉利德科学(GILD.US)超6亿美元囊获创新肿瘤免疫疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2423171813","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2423171813?lang=zh_cn&edition=full","pubTime":"2024-03-29 07:50","pubTimestamp":1711669808,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月29日，吉利德科学和Xilio Therapeutics宣布达成一项总额可能超过6亿美元的独家许可协议，两家公司将共同开发和商业化Xilio的肿瘤激活白介素12蛋白XTX301，该在研药物目前处于临床1期阶段。XTX301目前正在治疗晚期实体瘤患者的1期剂量递增试验中接受评估。在Xilio交付XTX301的指定临床数据后，吉利德可以选择获得XTX301的开发和商业化权利，并支付7500万美元的费用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1096048.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422529449","title":"【医疗健康周报】第12周：创新疫苗和佐剂开发商“华诺泰生物”获得6亿元人民币B轮融资；生物制药公司“CymaBay”以约43亿美元被吉利德并购","url":"https://stock-news.laohu8.com/highlight/detail?id=2422529449","media":"钛媒体APP","top":-1,"share":"https://www.laohu8.com/m/news/2422529449?lang=zh_cn&edition=full","pubTime":"2024-03-27 16:37","pubTimestamp":1711528648,"startTime":"0","endTime":"0","summary":"国内投融资方面，医药领域，创新疫苗和佐剂开发商“华诺泰生物”获得6亿元人民币B轮融资，核医学CRDMO“米度生物”融资近4亿元人民币。国外投融资方面，医药领域，生物制药公司“CymaBay”以约43亿美元被吉利德并购；生物技术领域，生物技术公司“Capstan Therapeutics”在B系列融资中筹集了1.75亿美元。医药“华诺泰生物”获得6亿人民币B轮融资日前，“华诺泰生物”正式宣布完成总额6亿元B轮融资。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271642038b68fa12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271642038b68fa12&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421071560","title":"吉利德科学下跌1.22%，报73.08美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2421071560","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2421071560?lang=zh_cn&edition=full","pubTime":"2024-03-22 03:53","pubTimestamp":1711050837,"startTime":"0","endTime":"0","summary":"3月22日，吉利德科学(GILD)盘中下跌1.22%，截至03:53，报73.08美元/股，成交2.72亿美元。财务数据显示，截至2023年12月31日，吉利德科学收入总额271.16亿美元，同比减少0.6%；归母净利润56.65亿美元，同比增长23.37%。大事提醒：4月25日，吉利德科学将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/22035339946722.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419655901","title":"吉利德科学下跌1.23%，报73.3美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419655901","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419655901?lang=zh_cn&edition=full","pubTime":"2024-03-16 00:02","pubTimestamp":1710518562,"startTime":"0","endTime":"0","summary":"3月16日，吉利德科学(GILD)盘中下跌1.23%，截至00:02，报73.3美元/股，成交2.59亿美元。财务数据显示，截至2023年12月31日，吉利德科学收入总额271.16亿美元，同比减少0.6%；归母净利润56.65亿美元，同比增长23.37%。大事提醒：4月25日，吉利德科学将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/16000239875543.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419237919","title":"到 2026 年，吉利德 CAR-T 癌症疗法的产能将翻两番","url":"https://stock-news.laohu8.com/highlight/detail?id=2419237919","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419237919?lang=zh_cn&edition=full","pubTime":"2024-03-15 18:00","pubTimestamp":1710496855,"startTime":"0","endTime":"0","summary":"吉利德公司在 2017 年斥资近 120 亿美元收购了 Kite 公司，后者是 CAR-T 疗法这一新兴领域的领军企业之一，目前可治疗多种血癌。公司希望扩大 CAR-T 在美国的整体覆盖范围和市场份额。自2017年以来，六种获批的CAR-T产品已在美国施用了超过2.7万剂。最近，吉利德的 CAR-T 收入增长放缓，2023 年第四季度两种疗法的销售额连续下滑，约为 4.56 亿美元。该公司上个月表示，预计第一季度的CAR-T销售额将与上一季度持平或略有增长，但今年下半年的增长将有所回升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419659245","title":"吉利德科学上涨1.23%，报76.0美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419659245","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419659245?lang=zh_cn&edition=full","pubTime":"2024-03-14 02:54","pubTimestamp":1710356075,"startTime":"0","endTime":"0","summary":"3月14日，吉利德科学(GILD)盘中上涨1.23%，截至02:54，报76.0美元/股，成交2.16亿美元。财务数据显示，截至2023年12月31日，吉利德科学收入总额271.16亿美元，同比减少0.6%；归母净利润56.65亿美元，同比增长23.37%。大事提醒：4月25日，吉利德科学将披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/14025439842219.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2417743147","title":"隔夜美股全复盘(3.8)| 三大股指集体收涨，英伟达涨逾4%，续创历史新高；诺和诺德大涨9%，口服减肥药Amycretin 3个月减重13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417743147","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2417743147?lang=zh_cn&edition=full","pubTime":"2024-03-08 05:21","pubTimestamp":1709846493,"startTime":"0","endTime":"0","summary":"三大股指集体收涨，英伟达涨逾4%，续创历史新高；诺和诺德大涨9%，口服减肥药Amycretin 3个月减重13%","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/703712","is_publish_highlight":false,"gpt_icon":0},{"id":"2417716283","title":"吉利德科学上涨1.21%，报73.51美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2417716283","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2417716283?lang=zh_cn&edition=full","pubTime":"2024-03-08 02:56","pubTimestamp":1709837792,"startTime":"0","endTime":"0","summary":"3月8日，吉利德科学(GILD)盘中上涨1.21%，截至02:56，报73.51美元/股，成交3.07亿美元。财务数据显示，截至2023年12月31日，吉利德科学收入总额271.16亿美元，同比减少0.6%；归母净利润56.65亿美元，同比增长23.37%。大事提醒：3月4日，吉利德科学获富国银行下调目标价至77美元，最新评级Equal Weight。4月25日，吉利德科学将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/08025639773438.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2417766651","title":"开发肿瘤靶向三特异性抗体！吉利德(GILD.US)与Merus达成超15亿美元合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2417766651","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2417766651?lang=zh_cn&edition=full","pubTime":"2024-03-07 21:26","pubTimestamp":1709817992,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月6日，吉利德宣布与Merus达成合作，双方将共同开发多款靶向新型肿瘤相关抗原的三特异性抗体。一旦行权，Merus将获得5600万美元的首付款以及2500万美元的股权投资，潜在交易金额超15亿美元。Merus官网公示的管线中均为双抗产品。2016年，Incyte与Merus就11个双特异性抗体达成合作。Incyte将支付1.2亿美元的预付款，并购买Merus8000万美元的普通股。此外，Merus还与礼来、先声药业、贝达药业等药企均有合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1083157.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417291502","title":"BUZZ-Merus 因与吉利德合作发现基于抗体的疗法而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2417291502","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417291502?lang=zh_cn&edition=full","pubTime":"2024-03-06 22:03","pubTimestamp":1709733794,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    3月6日 - ** 在美国上市的荷兰疗法开发商Merus NV   股价盘前上涨1.5%至50.70美元** 该公司称， (link)，它将与吉利德科学公司  合作，研究和开发治疗癌症的抗体疗法。 ** Merus公司将领导两个项目的早期研究活动，吉利德公司将有权许可合作项目的开发** Merus公司将为初期目标获得5600万美元的预付现金，吉利德公司将投资2500万美元购买Merus公司的普通股。** 公司还有资格在潜在的开发和商业化里程碑上获得高达 15 亿美元的收益** 截至上次收盘，股价在过去12个月中上涨了一倍多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413117767","title":"吉利德科学上涨1.21%，报73.66美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2413117767","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2413117767?lang=zh_cn&edition=full","pubTime":"2024-02-23 22:50","pubTimestamp":1708699854,"startTime":"0","endTime":"0","summary":"2月23日，吉利德科学(GILD)盘中上涨1.21%，截至22:50，报73.66美元/股，成交2772.43万美元。财务数据显示，截至2023年12月31日，吉利德科学收入总额271.16亿美元，同比减少0.6%；归母净利润56.65亿美元，同比增长23.37%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/02/23225039611130.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2413624820","title":"嗡嗡声--美国股票走势-Wayfair Inc、Remitly Global、Monopar Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2413624820","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413624820?lang=zh_cn&edition=full","pubTime":"2024-02-22 23:55","pubTimestamp":1708617309,"startTime":"0","endTime":"0","summary":"        *      个股异动的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      2月22日 - 在英伟达的出色业绩和预测刺激了今年人工智能引领的涨势之后，基准标普500指数周四短暂创下新纪录。美东时间10:31，道琼斯工业平均指数  上涨0.71%，报38888.1点。标准普尔500指数  上涨1.62%，报5062.63点；纳斯达克综合指数  上涨2.43%，报15959.39点。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413318297","title":"嗡嗡声--美国股票走势-Nvidia Corp、皇家加勒比、Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2413318297","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413318297?lang=zh_cn&edition=full","pubTime":"2024-02-22 20:13","pubTimestamp":1708604022,"startTime":"0","endTime":"0","summary":"        *      个股走势的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      2月22日 - 英伟达业绩和预期大丰收，推动华尔街今年以来屡创新高的人工智能热潮再次升温，周四纳斯达克指数跳涨约2%。美东时间7:02，道指电子盘  上涨0.36%，报38815点。标准普尔500指数  上涨1.28%，报5,060.25点；纳斯达克100指数  上涨2.10%，报17,904.5点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413919372","title":"BUZZ-Truist 下调吉利德评级并下调 PT 后，该公司股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2413919372","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413919372?lang=zh_cn&edition=full","pubTime":"2024-02-22 19:47","pubTimestamp":1708602474,"startTime":"0","endTime":"0","summary":"    2月22日 - ** 制药商吉利德科学  股价盘前下跌 ~1%，至 72.48 美元** 券商 Truist Securities 将吉利德的评级从 \"买入 \"下调至 \"持有\"，并将目标价从 91 美元下调至 82 美元。** 31家券商中有14家给予该股 \"买入 \"或更高评级，16家给予 \"持有 \"评级，1家给予 \"卖出 \"或更低评级；其PT中值为82.50美元--LSEG数据** 截至上次收盘，该股在过去12个月中下跌了13.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gilead.com","stockEarnings":[{"period":"1week","weight":-0.0175},{"period":"1month","weight":-0.0864},{"period":"3month","weight":-0.2253},{"period":"6month","weight":-0.1397},{"period":"1year","weight":-0.2011},{"period":"ytd","weight":-0.1738}],"compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":-0.024},{"period":"3month","weight":0.0505},{"period":"6month","weight":0.1884},{"period":"1year","weight":0.2084},{"period":"ytd","weight":0.0531}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"吉利德科学公司于1987年6月22日在特拉华州成立，是一家以研究为基础的生物制药公司，致力于发现，开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病，炎性和纤维化疾病以及肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.041198},{"month":2,"riseRate":0.393939,"avgChangeRate":0.002047},{"month":3,"riseRate":0.545455,"avgChangeRate":-0.009403},{"month":4,"riseRate":0.545455,"avgChangeRate":0.014542},{"month":5,"riseRate":0.5625,"avgChangeRate":0.021083},{"month":6,"riseRate":0.625,"avgChangeRate":0.024943},{"month":7,"riseRate":0.53125,"avgChangeRate":0.013302},{"month":8,"riseRate":0.53125,"avgChangeRate":0.033833},{"month":9,"riseRate":0.5625,"avgChangeRate":0.031735},{"month":10,"riseRate":0.5,"avgChangeRate":-0.00096},{"month":11,"riseRate":0.625,"avgChangeRate":0.039318},{"month":12,"riseRate":0.40625,"avgChangeRate":0.011587}],"exchange":"NASDAQ","name":"吉利德科学","nameEN":"Gilead Sciences"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉利德科学,GILD,吉利德科学股票,吉利德科学股票老虎,吉利德科学股票老虎国际,吉利德科学行情,吉利德科学股票行情,吉利德科学股价,吉利德科学股市,吉利德科学股票价格,吉利德科学股票交易,吉利德科学股票购买,吉利德科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}